NeurologyLive

NeurologyLive™ provides both print and digital media resources tailored for healthcare professionals focused on treating neurological disorders. It delivers vital news and insights straight from leading medical conferences and experts in the field. This platform offers a comprehensive overview of the numerous new treatments being developed, showcasing their innovative mechanisms of action. As the need for neurology specialists continues to rise, NeurologyLive™ keeps its audience informed with the latest clinical trial outcomes, FDA approvals, groundbreaking research, and expert opinions.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#344256

United States

#144752

Health/Health Conditions and Concerns

#343

Traffic sources

Monthly visitors

Articles

Aetna Joins UnitedHealthcare and Anthem in Authorizing PoNS Device Claims for Patients With MS

1 week ago | neurologylive.com | Marco Meglio

Helius Medical Technologies recently announced Aetna as the latest healthcare payer to provide coverage costs for the company’s Portable Neuromodulation Stimulator (PoNS) device, a non-implantable, orally applied therapy used to improve balance and gait in patients with multiple sclerosis (MS).
CGRP Therapy Atogepant Outperforms Topiramate in Head-to-Head TEMPLE Trial

1 week ago | neurologylive.com | Marco Meglio

Newly announced data from the phase 3 TEMPLE trial, a head-to-head study comparing atogepant (Qulipta; AbbVie) to topiramate (Topamax), 2 FDA-approved migraine medications, showed that atogepant met its primary end point, outperforming the anticonvulsant medication in both efficacy and safety measures.1 In this multicenter, double-blind, active-controlled trial, 545 patients with episodic or chronic migraine were randomly assigned to either atogepant or topiramate for a 24-week treatment...
Centessa to Advance Orexin Agonist ORX142 to Clinical Trials Following IND Acceptance

1 week ago | neurologylive.com | Marco Meglio

According to a recent announcement, the FDA has accepted Centessa Pharmaceuticals’ investigational new drug application (IND) for ORX142, an investigational orexin receptor 2 agonist (OX2R), to be tested in a phase 1 clinical study of healthy volunteers.1ORX142, which is being studied as a treatment for a select neurological and neurodegenerative disorders, will have its safety, tolerability, and pharmacokinetics evaluated in the phase 1 study.
Mendelian Randomization Analysis Identifies Neuroprotective and At-Risk Proteins for NMOSD

1 week ago | neurologylive.com | Marco Meglio

Increased plasma CLEC11A and SERPINA1 levels correlate with higher NMOSD risk, while elevated PF4V1 and FAM3B levels are linked to reduced risk. The study utilized 132 NMOSD patients and 1244 controls, applying the 2006 Wingerchuk diagnostic criteria for analysis. Sensitivity analyses confirmed no reverse causation, and drug target screening identified SERPINA1, CP, and TF as potential therapeutic targets.
Anti-Alpha-Synuclein Antibody Prasinezumab Enters Phase 3 Development

1 week ago | neurologylive.com | Marco Meglio

According to a new announcement, Roche is planning to advance its investigational anti-alpha-synuclein antibody prasinezumab into phase 3 trials of Parkinson disease (PD), further testing the agent’s therapeutic potential as a PD treatment.
Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment

1 week ago | neurologylive.com | Marco Meglio

Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder characterized by repeated upper airway collapse during sleep, leading to intermittent hypoxia, fragmented sleep, and excessive daytime sleepiness. Affecting an estimated 936 million adults globally, OSA poses a significant public health burden due to its associations with cardiovascular disease, metabolic disorders, cognitive impairment, and reduced quality of life.
12-Month Extension Data Highlights Ecopipam as an Effective Option for Tourette Syndrome

1 week ago | neurologylive.com | Marco Meglio

Data from an open-label extension (OLE) of a phase 2b study recently published in Movement Disorders showed that treatment with investigational ecopipam (Emalex Biosciences) was safe and effective in patients with Tourette syndrome (TS) over a 12-month period.
NeurologyLive® Brain Games: June 15, 2025

1 week ago | neurologylive.com | Marco Meglio

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
FDA Accelerated Approval Open for FSHD Agent Del-Brax, With Newly Initiated Phase 3 Study to Confirm Efficacy

2 weeks ago | neurologylive.com | Marco Meglio

In a number of company updates, Avidity Biosciences announced the FDA’s openness for an accelerated approval for its investigational agent delpacibart braxlosiran (del-brax) as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD).
Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury

2 weeks ago | neurologylive.com | Marco Meglio

Earlier this month, NervGen Pharma, a clinical-stage biotech company, announced topline data from its phase 1b/2a trial (NCT05965700) assessing its lead drug candidate, NVG-291, as a potential treatment for spinal cord injury (SCI).